The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA), was established in 2006 [4] and with more than 40,000 mutation carriers currently provides the largest sample size for reliable evaluation of even modest associations between single-nucleotide polymorphisms (SNPs) and cancer risk. This evidence concerns the gene BRCA1 and cancer.